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Purpose: The activity of the methanol extract of the whole plant of  Kalanchoe crenata (MEKC) was 
studied for the treatment of diabetes-induced nephropathy in rats. 
Methods: Five-day old Wistar rats received a single intraperitoneal streptozotocin injection (90 µg/kg 
body weight) to induce diabetes. Kidney disease onset in the rats was observed six weeks after 
diabetes induction. The rats were orally administered MEKC (0, 50 and 68 mg/kg) or glibenclamide (5 
mg/kg), once daily for 6 weeks. Blood and urine glucose, proteins, lipids, creatinine, malondialdehyde 
(MDA), superoxide dismutase (SOD) and catalase (CAT) were then evaluated.  
Results: After 6 weeks of treatment, 50 and 68 mg/kg MEKC, and glibenclamide significantly (p < 0.01) 
decreased glycaemia (-35, -44 and -39 %), glycosuria (-38, -47 and -61 %) and proteinuria (-82, -80 and 
-72 %) in diabetes-nephropathic rats. The extract (68 mg/kg) decreased MDA by up to -44 % (blood), -
35 % (liver) and -34 % (kidney); increased SOD up to 257 % (blood), 116 % (liver) and 118 % (kidney); 
and CAT by up to 176 % (blood), 78 % (liver) and 96 % (kidney) in the rats, compared with nephropathic 
control. The extract (50 and 68 mg/kg, respectively) lowered (p < 0.01) total cholesterolemia (-24 and -
27 %), blood triglycerides (-55 and -54 %), blood LDL cholesterol (-48 and -59 %), but increased blood 
HDL cholesterol (71 and 58 %). Overall, atherogenic index was decreased by 31 %.  
Conclusion: The results indicate that MEKC holds promise for the development of a standardized 
phytomedicine for diabetes mellitus and kidney disease treatment. 
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INTRODUCTION 
 
Diabetic nephropathy is one of the most 
serious complications of diabetes and the 
most common cause of end-stage renal 
failure in the world. Advanced diabetic 
nephropathy is characterized by specific 
renal morphological and functional 
alterations, proteinuria, declined renal 
function, decreasing creatinine clearance, 
glomerulosclerosis and interstitial fibrosis [1]. 
Diabetic kidney disease affects about 25 % of 
type 1 diabetic patients and 40 % of type 2 
diabetic patients [2]. Conventional treatment 
of diabetes mellitus includes inhibitor of α-
glycosidase, insulin and oral antihyper-
glycemic agents [3]. However, alternative 
therapies are also used, including plant 
products [4]. Approximately, 80 % of rural 
African communities still use phytotherapy to 
control or treat diabetes mellitus [3]. The 
search for appropriate hypoglycemic agents 
has focused partly on plants used in 
traditional medicine since natural products 
may be better treatments than currently used 
drugs; furthermore, several plants have been 
studied and found to possess antidiabetic 
properties [3].  
 
Kalanchoe crenata (Crassulaceae) is a 
vegetable widely used in Africa for the 
treatment of inflammatory diseases [5]. The 
antihyperglycemic potential of the water-
ethanol extract of this plant has been 
demonstrated [6]. Due to the inability of 
current medications to effectively treat certain 
diabetic complications such as nephropathy, 
it is desirable to explore other options 
inlcuding new drugs from plants. Thus, the 
present work focused on examining the 
justification for the traditional use of 
Kalanchoe crenata in the management of 







The whole plant of Kalanchoe crenata was 
collected in January and March 2008 from 
Batie (West Region, Cameroon) and 
identified by Dr. Onana of the National 
Herbarium of Yaounde (Cameroon) where a 
voucher specimen (no. 50103/YA) was kept. 
The whole plant was cleaned, shade-dried 
and powdered with a coffee mill (Délonghi- 
Burr milling system). The powder (2 kg) was 
macerated in 10 L of methanol (Analar grade, 
Normapur, Prolabo) for 72 h at room 
temperature. The filtrate concentrated under 
reduced pressure (i.e., under vacuum) 
yielded 113.6 g (5.68 %) of a dark green 
residue. This residue was then in n-hexane to 
remove its water-insoluble constituents. The 
final residue obtained after drying constituted 
the methanol extract of K. crenata (MEKC). 
The yield of the extract was 41.8 g (2.09 %). 
Prior to administration to the animals, the 
extract was re-constituted in distilled water 
and < 1 mL was given to each animal. 
 
Phytochemical screening test 
 
Phytochemical analysis of MEKC for its 
active biological principles was conducted 
using the methods, chemicals and reagents 
earlier described [6]: Mayer and Dragendoffs 
reagents for alkaloids; FeCl3 for tannin; 
frothing test for saponin; magnesium turning 
and HCl for flavonoids; NaCl and Fehlings 
solutions for glycoside; diethyl ether, 
sulphuric acid and anhydride acetic for 
steroids; ether-chloroform and NaOH for 
anthraquinones and FeCl3 and K3Fe(CN)6 for 
phenols and polyphenols. 
 
Acute toxicity evaluation  
 
MEKC was tested for its acute toxicity in 
mice. Five groups of six mice were orally 
administered either of the following doses of 
the extract: 2, 4, 6, 8, 10 g/kg body weight 
while the control group received vehicle 
(water). The animals were continuously 
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observed for the first 2 h for mortality and 
behavioral abnormalities: lethargy, jerkiness, 
sensitivity to sound and touch, and 
respiratory rate. They were then intermittently 
observed for the next 6 h, and at the 24th 
and 48th hour following drug administration. 
The lethal dose for 50 % of the mice (LD50) 
was determined using Eq 1 [7].   
 DL50 = Xs – d(p - ½) ............................... (1) 
 
Where Xs = lethal dose for 100 % of the 
mice, d = interval between the doses, p = 
proportion of death per group, and  p = sum 
of death proportions. 
 
Induction of kidney disease 
 
Male Wistar (5-day old) rats were obtained 
from the animal house of the Faculty of 
Science of the University of Yaounde I. They 
were maintained under natural laboratory 
conditions (temperature and dark/light cycle) 
and feeding by their mothers. Their mothers 
were allowed free access to food and water. 
Animal housing and experiments were 
according to the Guidelines of the European 
Union Directive on Ethical Evaluation of 
Animal Experiments (CEE Council 86/609) 
[8] and approved by the Institutional Ethics 
Committee of the Ministry of the Scientific 
Research and Innovation of Cameroon. 
 
Diabetes and nephropathy was induced in 
the 5-day old rats with a single intraperitoneal 
injection (i.p.) of 90 μg/kg body weight 
streptozotocin (STZ, Sigma Aldrich, no. SO 
130). The STZ (1.0 mL/kg) was freshly 
prepared in citrate buffer (0.01 M, pH 4.5) 
prior to use. Six weeks after STZ injection, 
blood glucose and urine protein levels were 
evaluated. The diabetic rats were charac-
terized by glycaemia > 225 mg/dL, and 
animals with kidney disease by proteinuria > 
3 g/L.  
 
Effect of the extract on the diseased rats 
 
In the experiment, 5 normal and 20 diabetic-
nephropathic rats were used. Nephropathic 
rats were randomly divided into four groups 
of 5 animals each. Normal control (NC) and 
diabetes-nephropathic control (DC) received 
distilled water; two groups of diabetes-
nephropathic rats were treated with 50 mg/kg 
(DK50) and 68 mg/kg (DK68), respectively, of 
the plant extract (MEKC). The diabetes-
nephropathic reference group (positive 
control) were treated with glibenclamide 
(Daonil, Laboratoires Hoechst) 5 mg/kg 
(DG5). These drugs were orally administered 
daily for six weeks using an orogastric tube. 
The effects of the extract on the diseased 
rats were evaluated from blood and urinary 
glucose, and urinary protein levels. After 6 
weeks of treatment, all the rats were fasted 
for 24 h and spot urine samples were 
collected to determine urinary glucose and 
protein levels. The rats were then ether-
anesthetized, decapitated and blood sample 
collected in plain and heparined tubes. From 
the clotted blood at room temperature, serum 
was collected after centrifugation (3000 rpm, 
10 min) and used to determine the levels of 
glucose, total cholesterol, triglycerides, and 
HDL cholesterol. Blood haemolysate and 
organ homogenates were prepared to assess 
thiobarbituric acid-reactive substances 
(TBARS, i.e., malondialdehyde (MDA), 
superoxide dismutase (SOD), and catalase 
(CAT) activities. The serum samples 
collected for biochemical assays were kept 
frozen at -20 ºC until used 
 
Preparation of serum, homogenate and 
hemolysate samples 
 
The rat organs (liver and kidney) were 
removed, weighed and placed immediately in 
ice-cold buffer (0.25M sucrose, 10mM Tris 
and 0.3 mM EDTA; pH 7.4) and washed 
thoroughly with distilled water to remove 
blood. The organs were homogenized 
separately using a Teflon homogenizer. The 
homogenate was centrifuged (15 min, 15 000 
rpm), the whole supernatant removed and 
frozen at -20 ºC pending subsequent tests. 
 
To prepare hemolysate, 100 μL of blood 
collected in tubes containing heparin was 
washed three times (by centrifugation at 
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3400 rpm for 5 mim) with 2 mL of NaCl (0.9 
%). After washing, the blood cells were 
hemolysed in 2 mL of distilled water. The 
resulting hemolysate was centrifuged (30 
min, 15000 rpm), and the supernatant was 
removed and kept frozen at –20 ºC pending 
further analysis. 
 
Serum and urine analysis 
 
Serum parameters were assayed using 
commercially available kits according to 
manufacturers’ recommendations. Glucose 
(Bio Direct Laboratories, La Villeneuve 
France), total cholesterol, triglyceride and 
HDL cholesterol (c.HDL) kits (Elitect 
Laboratories, SEPPIMS A. France) were 
employed. Cholesterol LDL (c.LDL) and 
atherogenic index (AI) were determined using 
the Eqs 2 and 3, respectively [9]. 
c.LDL =  T.C - (c.HDL + 
n
 TGs 
) .............. (2) 
AI = T.C – 
TC
 c.HDL 
 ............................... (3) 
Proteinuria was quantified by precipitation 
turbidimetric test of protein in acid 
trichloroacetic acid (TCA, 12 %) [10]. 
 
Determination of antioxidant activity of 
the extract 
 
TBARS (MDA) activity 
 
To estimate TBARS, 0.4 mL of homogenate 
or hemolysate was added to 2 mL of glacial 
acetic in a test tube. To this mixture was 
added 2 mL of 1 % thiobarbituric acid in 0.5M 
NaOH. The loosely stoppered tubes were 
immersed in boiling water bath for 1 h. The 
absorbance of the solutions in each tube, 
cooled under running tap water, was 
measured spectrophotometrically (Jenway 
Barloworld Scientific U.K.) at 532 nm against 




To assay SOD activity, 0.2 mL of 
homogenate or hemolysate was added to 2.5 
mL of sodium carbonate (0.05M, pH 10.2). 
The reaction began when 0.3 mL adrenaline 
was added. The reaction mixture was stirred 
vigorously and absorbance measured 
spectrophotometrically at 480 nm against 
blank (sodium carbonate + adrenaline 
+distilled water). The specific activity of SOD 
was expressed in units/mg protein. A unit is 
the quantity of SOD that inhibits 50 % 




The assessment of the catalase (CAT) 
activity was carried out spectrophoto-
metrically based on the decrease in 
absorbance at 570 nm against blank 
(reaction mixture + distilled water) [12]. The 
reaction mixture contained phosphate buffer 
(750 µl, 0.1M, pH7.5), H2O2 (200 µL, 50 mM) 
and solution of acetic acid + potassium 
dichromate (2 mL). The homogenate or 
hemolysate (50 µL) was added to the 
mixture. The specific activity of CAT was 




Data are expressed as mean ± SEM. 
Biochemical data were analyzed statistically 
using one-way ANOVA with Graphpad instat 
3.6, followed by Dunnett’s multiple-
comparison test. P values less than 0.05 




Phytochemical analysis of Kalanchoe crenata 
methanol extract (MEKC) revealed the 
presence of different classes of compounds 
including triterpenes, anthraquinones, 
phenols, tannins, sterols, phobotanins and 
polyphenols. 
 
Acute toxicity of extract 
 
In the acute toxicity test on the extract 
(MEKC), 4, 6, 8 and 10 g/kg doses reduced 
the sensitiveness of the rats to noise and 
touch,  which   also  showed    jerkiness   and  
Fondjo et al  

























































    
Figure 1: Blood glucose (A) and lipid (B) levels in STZ-induced diabetic nephropathy rats after 6-week daily treatment 
with K crenata methanol extract 50 mg/kg ( DK50) and 68 mg/kg ( DK68), glibenclamide 5 mg/kg ( DG5). normal 
control ( NC) and diabetic ( DC) control rats. Note:  TGs = triglycerides, TC = total cholesterol, c.HDL = HDL 
cholesterol, c.LDL = LDL cholesterol. Error bars denote SEM, n = 5. Significance difference: *p < 0.05 and **p < 0.01, 





















Figure 2: Atherogenic index of STZ-induced 
diabetic and nephropathic rats after 6-week daily 
treatment with K crenata methanol extract 50 
mg/kg (DK50) and 68 mg/kg (DK68), 
glibenclamide 5 mg/kg (DG5), normal (NC) and 
diabetic (DC) control rats. Error bars denote SEM, 
n = 5. **p < 0.01 compared with NC value; bp < 
0.01; compared with DC values. 
 
lethargy, and induced soft faeces and 66 % 
mice death within 30 min of administration. 
The 10 g/kg dose caused 100 % mice death. 
The lethal dose at 50% (LD50) was 4.4 g/kg. 
There were no gross behavioural changes. 
Macroscopically, the organs (liver, kidney 
and heart) did not show any discoloration. 
 
Effect of extract on blood and urine 
parameters 
 
In the experimental rats with kidney disease, 
12 weeks after onset of diabetes, significant 
(p < 0.01) increase in glycemia (68 %), total 
cholesterolemia (43 %), triglyceridemia (138 
%), blood LDL cholesterol (165 %), and 
atherogenic index (57 %) was observed (Figs 
1 and 2), while HDL cholesterol decreased 
markedly (-58 %). Compared with normal 
control, significant increase glucosuria (+90 
%) and proteinuria (+415 %) was observed in 
diabetes-nephropathic rats (Fig 3). 
 
After 6 weeks of treatment of the 
nephropathic rats, the extract (50 and 68 
mg/kg) and the glibenclamide (5 mg/kg) 
significantly (p < 0.01) reduced the blood 
level of the glucose (-35, -44, -39%, 
respectively) (Fig 1A), the triglycerides (-55, -
54, -52 % respectively), the total cholesterol 
(-24, -27, -27 %, respectively) and the LDL 
cholesterol (-48, -55, -59 % respectively). 
The cholesterol HDL level was enhanced by 
71 %, 58 % and 58 % (p < 0.01) respectively 
(Fig 1B) and hence decreased the 
atherogenic index (-35, -31, -31 % 
respectively, p < 0.01) (Fig 2). These drugs 
have  decreased  (p < 0.01)  the  glucosuria 
(-38, -47, -61 % respectively) and the 
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Figure 3: Urinary glucose and protei n levels in 
STZ-induced diabetic and nephropathic rats after 
6-week daily treatment with K crenata methanol 
extract 50 mg/kg ( DK50) and 68 mg/kg 
( DK68), glibenclamide dose of 5 mg/kg 
( DG5), normal ( NC) and diabetic ( DC) 
control rats. Error bars denote SEM, n = 5. 
Significance difference: *p < 0.01 compared with 
NC value; bp < 0.01 compared with DC values. 
 
Antioxidant activity of the extract 
 
Compared with normal rats, there was a 
significant (p < 0.01) increase in TBARS 
(MDA) concentration in tissue and 
hemolysate by 63 - 98 %. However, 
significant decrease in CAT levels by 
between 55 - 70 %, and SOD levels by 67 - 
78 % were observed (Figs 4 and 5). In 
hemolysate, as in liver and kidney, treatment 
of the rats with the extract and glibenclamide 
(reference standard) for 6 weeks lowered (p 
< 0.01) MDA level by 34 - 44 %, but 
increased CAT levels by 78 – 176 %, and 

































Figure 4: Lipid peroxidation, expressed as 
malondialdehyde (MDA) levels, in rat blood, liver 
and kidney after 6-week daily treatment with K 
crenata methanol extract (MEKC). Note: normal 
( NC and diabetic ( DC) control rats; diabetic 
nephropathic rats treated with 50 mg/kg ( DK50) 
and 68 mg/kg ( DK68) extract, and with 5 mg/kg 
glibenclamide ( DG5). Error bars denote SEM, 
n = 5. *p < 0.05 and **p < 0.01 compared with NC 



































































Figure 5: Catalase (CAT, A) and superoxide dismutase (SOD, B) activities in diabetes-nephropathic rats 
after 6-week daily treatment with K crenata methanol extract dose of 50 mg/kg ( DK50) and 68 mg/kg 
( DK68), and with 5 mg/kg glibenclamide ( DG5) in normal ( NC) and diabetic ( DC) control rats. 
Error bars denote SEM, n = 5. **p < 0.01 compared with NC group; ap < 0.05 and bp < 0.01 compared with 
DC group 
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DISCUSSION 
 
This study assessed the effect of K. crenata 
methanolic extract, a plant traditionally used 
in treatment of diabetes mellitus, on 
glyceamia, lipidemia, glucosuria, proteinuria 
and antioxidant activities expressed as SOD, 
CAT, and MDA in diabetes-induced nephro-
pathy in rats. 
 
In the acute toxicity study, single oral dose of 
up to 2 g/kg of the methanol extract was not 
lethal to male and female mice. The apparent 
cause of death of mice in the current study at 
the doses of 4, 6, 8 and 10 g/kg might be due 
to respiratory depression; it is noteworthy that 
the water-alcohol extract of K. crenata did not 
show lethality in a previous acute toxicity 
study [6]. The results suggest that MEKC 
possesses low toxicity since its LD50 (5 g/kg) 
is 65 and 88 times the test treatment doses 
[13]. 
 
In this study, STZ-induced diabetes resulted 
in toxic changes in kidney, blood and liver. 
These changes were indicated by increase in 
lipid peroxidation and decrease in CAT and 
SOD activities. SOD and CAT are the two 
major scavenging enzymes that remove toxic 
free radicals in vivo. SOD protects tissues 
against oxygen free radicals by catalyzing the 
removal of superoxide radical (O2-), which 
damages membrane and cell, while CAT has 
been shown to be responsible for the 
detoxification of significant amounts of 
peroxides. Reduced activities of SOD and 
CAT activities in the liver and hemolysate 
have been associated with diabetic 
nephropathy in rats, leading to a number of 
deleterious effects due to the accumulation of 
superoxide radicals and hydrogen peroxide 
[14]. 
 
Increase in lipid peroxidation in diabetic 
nephropathy may cause peroxidative tissue 
damage and inflammation [15]. Treatment of 
the rats with K crenata extract and 
glibenclamide exhibited antioxidant effect by 
increasing CAT and SOD activities, and 
decreasing MDA levels. Restoration of CAT 
and SOD activities, and MDA level in tissue 
and hemolysate to normal levels, may be due 
to the presence of polyphenols, triterpenes 
and tannins in the extract as they are known 
to possess antioxidant properties [16]. It is 
also probable that K. crenata brought about 
its hypoglycemic action through terpenoids 
that are known to reduce glycemia through 
many mechanisms which include insulin-like 
activity, inhibition of gluconeogenesis and 
glycogenolysis [3].  
 
The increase in urine protein level might have 
resulted from capillary glomerular 
hypertrophy or long-term damage that usually 
leads to increase in glomerular filtration and 
glomerular urinary protein [17]. Increase in 
proteinuria could have led to the 
accumulation of filtered protein in the 
cytoplasm of the proximal tubular cells, which 
is associated with interstitial inflammatory 
reaction and damage of glomerular and 
kidney tubule [17]. 
 
Oxidant stress markers (CAT, SOD and 
MDA), which are critical factors in the 
progression of diabetic nephropathy, are 
increased by inflammatory mechanisms of 
injury in the kidney [1,18]. Both glibenclamide 
and MEKC markedly decreased the level of 
proteinuria in the nephropathic rats probably 
lowering glomerular protein filtration and, in 
the case of the extract, this may be due to the 
presence of polyphenols, triterpenes and 




and enhanced glomerular lipid synthesis 
have been implicated in diabetic 
glomerulosclerosis and known to exercebate 
kidney diseases [19]. Increased local lipid 
synthesis appears to be stimulated in 
diabetes by a number of factors, including 
increased renal expression of transcription 
factor, sterol regulatory element binding 
protein-1 [20]. This endogenous kidney lipid 
synthesis pathway appears to directly result 
in enhanced accumulation of intracellular 
matrix proteins, mesangial expansion and 
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glomerulosclerosis [20], suggesting that 
diabetes induces renal glomerular synthesis 
of triglycerides and cholesterol, which then 
promotes  glomerulosclerosis. Both MEKC- 
and glibenclamide-treated rats exhibited 
decrease in total cholesterol, triglycerides, 
atherogene index and LDL cholesterol levels, 
and increase in HDL cholesterol level and 
thus could have a beneficial effect on 
accumulation of intracellular matrix proteins, 
glomerulosclerosis and renal expression of 
the transcription factor, sterol regulatory 





The results show that the methanol extract of 
K. Crenata, at 50 and 68 mg/kg body weight 
doses, through its lowering effect on SOD 
and CAT activities enhanced MDA level, and 
thus decreased glyceamia, lipidemia, 
glucosuria and proteinuria. Therefore, the 
extract possesses anti-diabetic and anti-
nephropathic activities which may explain the 
traditional use of this plant for management 
of diabetes and its complications. Hence, the 
active fraction of the extract could be 
promising for the development of a 
standardized phytomedicine for the treatment 
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